In this video from the American Academy of Ophthalmology meeting, Philip J. Ferrone, MD, discusses the TEASE-2 trial results in treating Stargardt disease with gildeuretinol.
Battery life remains the headline. HyperX's previous Cloud Alpha Wireless —a long‑standing PC Gamer favorite for best ...
We show that, compared with surgeon predictions and existing risk-prediction tools, our machine-learning model can enhance ...
The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody commonly used in standard regimens for HER2-positive breast cancer. FDA ...
A research team led by NIMS has, for the first time, produced nanoscale images of two key features in an ultra-thin material: ...
In TUXEDO-2, ticagrelor failed to meet the bar for noninferiority, with most outcomes hinting at an advantage for prasugrel.
Google DeepMind’s new AI agent learned how to play a bunch of video games — including No Man’s Sky, Valheim, and Goat ...
By early 2026, substance use disorder (SUD) providers, health plans, clinicians, health information exchanges (HIEs), and vendors must meet ...
We appreciate the constructive remarks by Chung-Wei Christine Lin and colleagues regarding our systematic review and resulting recommendations.1 Our systematic review and meta-analysis were explicitly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback